Organogenesis Holdings (ORGO) Cost of Revenue (2017 - 2026)

Organogenesis Holdings has reported Cost of Revenue for 10 years, with the latest figure at $23.7 million in Q2 2026.

• On a quarterly basis, Cost of Revenue fell 14.32% year-over-year to $23.7 million in Q2 2026; TTM through Jun 2026 was $135.6 million, a 24.19% increase from a year earlier, with the FY2025 full-year figure at $137.5 million, up 18.82% from the prior year.
• Cost of Revenue was $23.7 million for Q2 2026 at Organogenesis Holdings, down from $25.8 million in the prior quarter.
• The five-year high for Cost of Revenue was $49.9 million in Q4 2025, with the low at $23.7 million in Q2 2026.
• Average Cost of Revenue over 5 years is $28.6 million, with a median of $26.7 million recorded in 2022.
• The largest YoY upside for Cost of Revenue was 60.76% in 2025 against a maximum downside of 17.33% in 2025.
• Over 5 years, Cost of Revenue stood at $27.1 million in 2022, then gained by 2.43% to $27.8 million in 2023, then grew by 11.82% to $31.1 million in 2024, then jumped by 60.76% to $49.9 million in 2025, then tumbled by 52.58% to $23.7 million in 2026.
• The last three Cost of Revenue figures came in at $23.7 million (Q2 2026), $25.8 million (Q1 2026), and $49.9 million (Q4 2025), per Business Quant data.